Bayer/PPD Implitapide Development Follows Zetia Model As Statin Add-On
PPD will adopt Merck/Schering-Plough's Zetia model in developing Bayer's implitapide as an add-on therapy in the lipid-lowering market, PPD subsidiary MRL International CEO Evan Stein, MD/PhD, said
You may also be interested in...
Recruitment for Schering-Plough's sales force expansion is 80% complete, Global Pharmaceutical President Carrie Cox told investors during a year-end conference call Jan. 26
Merck/Schering's Zetia/Zocor fixed-dose combination will be positioned as a first-line, cholesterol-lowering therapy, while Zetiawill be reserved primarily for the niche population of patients who are not at their target cholesterol levels
Bristol-Myers Squibb's Pravachol is gaining share in the retail market in the early days following the withdrawal of Bayer's Baycol, prescription tracking data from ArcLight indicate.